Tralokinumab for moderate-to-severe UC: a randomised, double-blind, placebo-controlled, phase IIa study.
Fiche publication
Date publication
février 2015
Journal
Gut
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
Danese S, Rudziński J, Brandt W, Dupas JL, Peyrin-Biroulet L, Bouhnik Y, Kleczkowski D, Uebel P, Lukas M, Knutsson M, Erlandsson F, Hansen MB, Keshav S
Lien Pubmed
Résumé
Interleukin-13 (IL-13) has been implicated as a key driver of UC. This trial evaluates the efficacy and safety of tralokinumab, an IL-13-neutralising antibody, as add-on therapy in adults with moderate-to-severe UC despite standard treatments.
Mots clés
ULCERATIVE COLITIS
Référence
Gut. 2015 Feb;64(2):243-9